

IN THE UNITED STATÉS PATENT AND TRADEMARK OFFICE

JC17 Rec'd PCT/PTO 10 JUN 2005

In re application of: Chung-Il HONG et al. Int'l Application No.: PCT/KR2003/002700

Int'l Filing Date: December 10, 2003

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Appl. No.: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Filed: June 10, 2005

Atty. Docket No.: 36470-218722

Customer No.

ORAL FORMULATIONS FOR POORLY ABSORPTIVE HYDROPHILIC DRUGS

26694
PATENT TRADEMARK OFFICE

Information Disclosure Statement

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 Attention: PCT DO/EO/US

Sir:

For:

This is an Information Disclosure Statement submitted within the time limit specified under 37 C.F.R. § 1.97(b).

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of documents A1- A21 which are listed on the attached Form PTO/SB/08A. The Examiner may deem these documents relevant to the patentability of the claims of the above-identified application. Documents A1-A8 are not being provided. Copies of A20 and A21 will be submitted in the near future.

The relevance of documents A1-A6 and A9-A17 is indicated in the above-referenced application. The relevance of documents A7-A8 and A18-A19 is indicated in the attached International Search Report of International Application No. PCT/KR2003/002700.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Applicant(s): Chung-Il HONG et al. Int'l Appl. No.: PCT/KR2003/002700

In view of the above, no further translation or statement of relevance is required. Additionally, since all requirements of 37 C.F.R. § 1.97 and all official guidelines pertaining to Information Disclosure Statements have been met, it is respectfully requested that the documents be considered by the Examiner and made of record.

Please charge any necessary fee, or credit any overpayment in connection with this Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfully submitted,

Marina V. Schneller

Registration No. 26,032

VENABLE LLP P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000 Telefax: (202) 344-8300

MVS/cdw 652718

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

1

Sheet

INFORMATION DISCLOSURE STATE

(use

MATION DISCLOSURE			Filing Date	June 10, 2005	
MENT E	BY A	PPLICANT	First Named Inventor	Chung-Il HONG et al.	
			Group Art Unit	Not Yet Assigned	·
se as many sheets as necessary)			Examiner Name	Not Yet Assigned	
	of	1	Attorney Docket Number	36470-218722	

Application Number

	U.S. PATENT DOCUMENTS						
		U.S. Patent Doc	ument	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevan	
	Cite No. ¹	Number Kind (Code ² own)			Passages or Relevant Figures Appear	
/C.S./	A1	3,882,243		Tadao MAEDA et al.	05-06-1975		
8	A2	2002/0015730	A1	Torsten HOFFMANN et al.	02-07-2002		
000	A3	5,929,027	Α	Shigeyuki TAKAMA et al.	07-27-1999		
	A4	5,665,711	A	Atsushi SAKAI et al. 09-09-1997			
	A5	5,318,781	A	Navnit SHAH et al.	06-07-1994		
\ /	A6	4,397,951	· ·	Kazuo TAKI et al.	08-09-1983		
₩	A7	6,184,037	BI	Alain ROLLAND et al.	02-06-2001		
/C.S./	A8	6,200,602	Bı	Peter James WATTS et al.	03-13-2001		

			F.O	REIGN	PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Office ³		nt Code ⁵ (<i>if</i> own)	Name of Patentee or Applicant of	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant	T ₆
/c.s./	A9	DE	40 03 844	A1	Cited Document	08-16-1990	Figures Appear	
ğ	A10	EP	0 230 332	Al		07-29-1987		
	A11	KR	2001-0042083			05-25-2001	w/English Abstract	
	A12	KR	103209			04-22-1988	w/English Abstract	
	A13	wo	00/25598	A1		05-11-2000		
	A14	WO	94/25062	Al		11-10-1994		
8	A15	KR	026778	B1		12-14-1983	w/English Abstract	
	A16	EP	0 983 769	A1		03-08-2000		
	A17	EP	0 702 958	Al		03-27-1996		
	A18	KR	2001-0006361			01-26-2001	w/English Abstract	
V	A19	KR	020298	B1		12-03-1982	w/English Abstract	
C.S./	A20	WO	98/01159	A2		01-15-1998		
		ОТ	HER PRIOR AR	T NO	N PATENT LITE	RATURE DOCUME	ENTS	
Examiner nitials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
/C.S./	A21	E.S. SWENSON et al., (C) MEANS TO ENHANCE PENETRATION, (2) INTESTINAL PERMAEBILITY ENHANCEMENT FOR PROTEINS, PEPTIDES AND OTHER POLAR DRUGS: MECHANISMS AND POTENTIAL TOXICITY, Advanced Drug Delivery Reviews, 1992, Vol. 8, No. 1, Pages 39-92.						

	- · · · · ·		
Examiner Signature	/Christopher Stone/	Date Considered	06/03/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.